Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

By R. Herbst, G. Giaccone, J. Schiller, R. Natale, Vincent A. Miller, C. Manegold, G. Scagliotti, R. Rosell, I. Oliff, J. Reeves and 7 more. Journal of Clinical Oncology, 2004

1,775 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/4432aafb92562b8216a4647463aea577bd2181ab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. B. Chan
2. D. Stewart
3. William Pao
4. B. Hughes
5. J. Schiller
6. K. Imai
7. A. Takaoka

In Oncology

1. D. Stewart
2. William Pao
3. K. Imai
4. A. Takaoka

In Pulmonary and Respiratory Medicine

1. B. Hughes
2. B. Chan
3. D. Stewart
4. William Pao
5. K. Imai
6. A. Takaoka

Citations in the corpus

• Chemotherapy and the war on cancer (2005, background): “, but failed to increase activity of chemotherapy in large randomized trial”
• Mechanisms of resistance to cisplatin and carboplatin. (2007, background): “[274] Herbst RS, Giaccone G, Schiller JH, et al.”
• Comparing antibody and small-molecule therapies for cancer (2006, background): “The combination of gefitinib with two different chemotherapy regimens in advanced NSCLC did not result in any additive effects over chemotherapy alone in two large randomized studie”
• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “The INTACT 1 (48) and INTACT 2 (49) looked at gefitinib whereas the TRIBUTE (50) and TALENT (51) trials used erlotinib.”